Haemonetics Co. (NYSE:HAE) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Haemonetics Co. (NYSE:HAE - Get Free Report) have received a consensus rating of "Moderate Buy" from the nine analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $101.22.

A number of research firms recently commented on HAE. StockNews.com lowered Haemonetics from a "buy" rating to a "hold" rating in a research report on Saturday, February 15th. Barrington Research dropped their price objective on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. Raymond James restated a "strong-buy" rating and issued a $115.00 target price (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Needham & Company LLC cut their price target on Haemonetics from $108.00 to $104.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th. Finally, JMP Securities decreased their price objective on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a report on Friday, February 7th.

Institutional Investors Weigh In On Haemonetics

Large investors have recently added to or reduced their stakes in the business. Thrivent Financial for Lutherans boosted its position in shares of Haemonetics by 14.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock valued at $98,716,000 after acquiring an additional 164,111 shares during the last quarter. Boston Trust Walden Corp grew its stake in Haemonetics by 22.1% in the 1st quarter. Boston Trust Walden Corp now owns 1,118,331 shares of the medical instruments supplier's stock worth $71,070,000 after buying an additional 202,609 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Haemonetics by 1.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier's stock worth $77,470,000 after buying an additional 10,990 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Haemonetics by 20.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 966,167 shares of the medical instruments supplier's stock worth $60,888,000 after buying an additional 165,118 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Haemonetics by 3.2% during the 4th quarter. Fisher Asset Management LLC now owns 711,774 shares of the medical instruments supplier's stock valued at $55,575,000 after buying an additional 22,265 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Trading Down 1.4 %

Shares of HAE stock traded down $0.92 during trading hours on Friday, hitting $63.05. 552,251 shares of the company were exchanged, compared to its average volume of 689,703. Haemonetics has a fifty-two week low of $55.30 and a fifty-two week high of $97.97. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The firm has a market cap of $3.17 billion, a P/E ratio of 24.82, a P/E/G ratio of 1.11 and a beta of 0.41. The company has a 50 day simple moving average of $62.82 and a two-hundred day simple moving average of $71.91.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Equities analysts anticipate that Haemonetics will post 4.55 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.